In bladder cancers, stromal CAFs enhanced cisplatin resistance via stimulating IGF-1/ERbeta/Bcl-2 signaling, wherein CAFs regulated ERbeta expression through IGF-1/AKT/c-Jun signaling following c-Jun phosphorylation and promoted ESR2 gene transcription [48]. This evidence concerns the gene ESR2 and urinary bladder carcinoma.